Login / Signup

Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus Erythematosus.

Minji AiXian ZhouMichele CarrerPaymaan Jafar-NejadYanfeng LiNaomi Gades D V MMariam P AlexanderMario A BautistaAli A Duarte GarciaHu Zeng
Published in: bioRxiv : the preprint server for biology (2024)
Targeting mTORC2 could be a promising therapeutic for SLE.
Keyphrases
  • cancer therapy
  • systemic lupus erythematosus
  • disease activity
  • drug delivery